cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2021-3076cardiovascular-3076Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMПатогенез атеросклероза через призму нарушения функций микрососудовAtherosclerosis pathogenesis from the perspective of microvascular dysfunctionhttps://orcid.org/0000-0003-0484-9805АроновД. М.AronovD. M.

Аронов Давид Меерович — доктор медицинских наук, профессор, заслуженный деятель науки РФ, главный научный сотрудник

Москва

Moscow

aronovdm@mail.ruhttps://orcid.org/0000-0003-2250-5942БубноваМ. Г.BubnovaM. G.

Бубнова Марина Геннадьевна — доктор медицинских наук, профессор, руководитель отдела реабилитации и вторичной профилактики сердечно-сосудистых заболеваний

Москва

Moscow

mbubnova@gnicpm.ruhttps://orcid.org/0000-0001-6581-4521ДрапкинаО. М.DrapkinaO. M.

Драпкина Оксана Михайловна — доктор медицинских наук, профессор, член-корреспондент РАН, директор

Москва

Moscow

drapkina@bk.ruФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава РоссииNational Medical Research Center for Therapy and Preventive Medicine20211711202120730763076Copyright © Аронов Д.М., Бубнова М.Г., Драпкина О.М., 20212021Аронов Д.М., Бубнова М.Г., Драпкина О.М.Aronov D.M., Bubnova M.G., Drapkina O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/3076

В статье обсуждаются разные точки зрения исследователей на формирование атеросклероза. Приводятся факты, подтверждающие “холестериновую теорию атерогенеза”. Обращается внимание на возможное участие в  развитии атеросклероза микрососудов кровеносной системы — vasa vasorum.

The article discusses different points of view on atherosclerosis development. The facts confirming the lipid hypothesis are presented. Attention is drawn to the possible participation of vasa vasorum in the development of atherosclerosis.

холестеринмикрососудыатеросклерозсердечно-сосудистые заболеванияcholesterolmicrovesselsatherosclerosiscardiovascular diseasesReferencesAnitschkow N, Chalatow S. Ueber experimentelle Cholesterinsteatose und ihre Bedeutung fuer die Entstehung einiger pathologischer Prozesse. Zentrbl Allg Pathol Pathol Anat. 1913;24:1-9.Anitschkow N, Chalatow S. Ueber experimentelle Cholesterinsteatose und ihre Bedeutung fuer die Entstehung einiger pathologischer Prozesse. Zentrbl Allg Pathol Pathol Anat. 1913;24:1-9.Anichkov NN. Experimental arteriosclerosis in animals. In: Cowdry EV, editor, Arteriosclerosis: A survey of the problem. New York: MacMillan Publishing. 1933. p. 271-322.Anichkov NN. Experimental arteriosclerosis in animals. In: Cowdry EV, editor, Arteriosclerosis: A survey of the problem. New York: MacMillan Publishing. 1933. p. 271-322.Anitschow NN. Deuxieme conference international de pathologie geographyque. Oosthoek;1935.Anitschow NN. Deuxieme conference international de pathologie geographyque. Oosthoek;1935.Климов А. Н. К спорам о холестерине. Кардиология.1992;2:3-8.Klimov AN. To the debate about cholesterol. Kardiologiia. 1992;2:3-8. (In Russ.)Davies H. Atherogenesis and the coronary arteries of childhood. Int J Cardiol. 1990;28(3):283-91. doi:10.1016/0167-5273(90)90310-2.Davies H. Atherogenesis and the coronary arteries of childhood. Int J Cardiol. 1990;28(3):283-91. doi:10.1016/0167-5273(90)90310-2.Haverich A, Boyle E. Atherosclerosis Pathogenesis and Microvascular Dysfunction. Springer, 2019. 130 p. ISBN: 978-3-030-20244-6.Haverich A, Boyle E. Atherosclerosis Pathogenesis and Microvascular Dysfunction. Springer, 2019. 130 p. ISBN: 978-3-030-20244-6.Kannel WB, Dawber TR, Kagan A, et al. Factors of risk in the development of coronary heart disease — six-year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55:33- 50. doi:10.7326/0003-4819-55-1-33.Kannel WB, Dawber TR, Kagan A, et al. Factors of risk in the development of coronary heart disease — six-year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55:33- 50. doi:10.7326/0003-4819-55-1-33.Stehbens WE. Coronary heart disease, hypercholesterolemia, and atherosclerosis I. False premises. Exp Mol Pathol. 2001;70:103-19. doi:10.1006/exmp.2000.2340.Stehbens WE. Coronary heart disease, hypercholesterolemia, and atherosclerosis I. False premises. Exp Mol Pathol. 2001;70:103-19. doi:10.1006/exmp.2000.2340.Stehbens WE. Coronary heart disease, hypercholesterolemia, and atherosclerosis II. Misrepresented Data. Exp Mol Pathol. 2001;70:120-39. doi:10.1006/exmp.2000.2339.Stehbens WE. Coronary heart disease, hypercholesterolemia, and atherosclerosis II. Misrepresented Data. Exp Mol Pathol. 2001;70:120-39. doi:10.1006/exmp.2000.2339.Niccoli G, Camici PG. Myocardial infarction with non-obstructive coronary arteries: what is the prognosis? Eur Heart J. 2020;22(Suppl E):E40-5. doi:10.1093/eurheartj/suaa057.Niccoli G, Camici PG. Myocardial infarction with non-obstructive coronary arteries: what is the prognosis? Eur Heart J. 2020;22(Suppl E):E40-5. doi:10.1093/eurheartj/suaa057.Lüscher TF. Revisiting angina pectoris with and without obstructive coronary artery disease. Eur Heart J. 2018; 39(23):2119-22. doi:10.1093/eurheartj/ehy335.Lüscher TF. Revisiting angina pectoris with and without obstructive coronary artery disease. Eur Heart J. 2018; 39(23):2119-22. doi:10.1093/eurheartj/ehy335.Kaski JC, Crea F, Gersh BJ, Camici PG. Reappraisal of Ischemic Heart Disease. Circulation. 2018;138(14):1463-80. doi:10.1161/CIRCULATIONAHA.118.031373.Kaski JC, Crea F, Gersh BJ, Camici PG. Reappraisal of Ischemic Heart Disease. Circulation. 2018;138(14):1463-80. doi:10.1161/CIRCULATIONAHA.118.031373.McMichael J. Fats and atheroma: an inquest. Br Med. 1979;1:173-5. doi:10.1136/bmj.1.6157.173.McMichael J. Fats and atheroma: an inquest. Br Med. 1979;1:173-5. doi:10.1136/bmj.1.6157.173.Allam AH, Thompson RC, Wann LS, Miyamoto MI et al. Atherosclerosis in ancient Egyptian mummies: the Horus study. JACC Cardiovasc Imaging. 2011;4(4):315-27. doi:10.1016/j.jcmg.2011.02.002.Allam AH, Thompson RC, Wann LS, Miyamoto MI et al. Atherosclerosis in ancient Egyptian mummies: the Horus study. JACC Cardiovasc Imaging. 2011;4(4):315-27. doi:10.1016/j.jcmg.2011.02.002.Dayton S, Pearce ML. Diet high in unsaturated fat. A controlled clinical trial. Minn Med. 1969;52:1237-42. doi:10.1161/01.cir.40.1s2.ii-1.Dayton S, Pearce ML. Diet high in unsaturated fat. A controlled clinical trial. Minn Med. 1969;52:1237-42. doi:10.1161/01.cir.40.1s2.ii-1.DuBroff R, de Lorgeril M. Cholesterol confusion and statin controversy. World J Cardiol. 2015;7:404-9. doi:10.4330/wjc.v7.i7.404DuBroff R, de Lorgeril M. Cholesterol confusion and statin controversy. World J Cardiol. 2015;7:404-9. doi:10.4330/wjc.v7.i7.404Chiuve SE, Fung TT, Rexrode KM, et al. Adherence to a low-risk, healthy lifestyle and risk of sudden cardiac death among women. JAMA. 2011;306(1):62-9. doi:10.1001/jama.2011.907.Chiuve SE, Fung TT, Rexrode KM, et al. Adherence to a low-risk, healthy lifestyle and risk of sudden cardiac death among women. JAMA. 2011;306(1):62-9. doi:10.1001/jama.2011.907.Åkesson A, Larsson SC, Discacciati A, Wolk A. Low-risk diet and lifestyle habits in the primary prevention of myocardial infarction in men: a population-based prospective cohort study. J Am Coll Cardiol. 2014;64:1299-306. doi:10.1016/j.jacc.2014.06.1190.Åkesson A, Larsson SC, Discacciati A, Wolk A. Low-risk diet and lifestyle habits in the primary prevention of myocardial infarction in men: a population-based prospective cohort study. J Am Coll Cardiol. 2014;64:1299-306. doi:10.1016/j.jacc.2014.06.1190.Cho Y, Jeong Y, Seo DH, et al. Use of statin for the primary prevention of cardiovascular outcomes in elderly patients: A propensity-matched cohort study. Atherosclerosis. 2021;328:92- 9. doi:10.1016/j.atherosclerosis.2021.05.022.Cho Y, Jeong Y, Seo DH, et al. Use of statin for the primary prevention of cardiovascular outcomes in elderly patients: A propensity-matched cohort study. Atherosclerosis. 2021;328:92- 9. doi:10.1016/j.atherosclerosis.2021.05.022.Gofman JW, Lindgren F. The role of lipids and lipoproteins in atherosclerosis. Science. 1950;111:166-71. doi:10.1126/science.111.2877.166.Gofman JW, Lindgren F. The role of lipids and lipoproteins in atherosclerosis. Science. 1950;111:166-71. doi:10.1126/science.111.2877.166.Gofman JW, Lindgren FT, Elliott H. Ultracentrifugal studies of lipoproteins of human serum. J Biol Chem. 1949;179:973-9.Gofman JW, Lindgren FT, Elliott H. Ultracentrifugal studies of lipoproteins of human serum. J Biol Chem. 1949;179:973-9.Gofman JW, Jones HB, Lindgren FT, et al. Blood lipids and human atherosclerosis. Circulation. 1950;2:161-78. doi:10.1161/01.cir.2.2.161.Gofman JW, Jones HB, Lindgren FT, et al. Blood lipids and human atherosclerosis. Circulation. 1950;2:161-78. doi:10.1161/01.cir.2.2.161.Keys A. Atherosclerosis: a problem in newer public health. J Mt Sinai Hosp N-Y. 1953;20:118-39.Keys A. Atherosclerosis: a problem in newer public health. J Mt Sinai Hosp N-Y. 1953;20:118-39.Keys A, Anderson JT, Fidanza F, et al. Effects of diet on blood lipids in man. Clin Chem. 1955;1:34.Keys A, Anderson JT, Fidanza F, et al. Effects of diet on blood lipids in man. Clin Chem. 1955;1:34.Yerushalmy J, Hilleboe HE. Fat in the diet and mortality from heart disease; a methodologic note. N Y State J Med. 1957;57:2343-54.Yerushalmy J, Hilleboe HE. Fat in the diet and mortality from heart disease; a methodologic note. N Y State J Med. 1957;57:2343-54.Keys A, Blackburn H, Menotti A, et al. Coronary heart disease in seven countries. Circulation. 1970; 41(Suppl 1):1-211.Keys A, Blackburn H, Menotti A, et al. Coronary heart disease in seven countries. Circulation. 1970; 41(Suppl 1):1-211.Steinberg D. Lowering blood cholesterol to prevent heart disease. NIH Consensus Development Conference statement. Arterioscler Thromb Vasc Biol. 1985;5:404-12.Steinberg D. Lowering blood cholesterol to prevent heart disease. NIH Consensus Development Conference statement. Arterioscler Thromb Vasc Biol. 1985;5:404-12.Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205. doi:10.1016/j.atherosclerosis.2019.08.014.Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205. doi:10.1016/j.atherosclerosis.2019.08.014.Jha HC, Prasad J, Mittal A. High immunoglobulin A seropositivity for combined Chlamydia pneumoniae, Helicobacter pylori infection, and high-sensitivity C-reactive protein in coronary artery disease patients in India can serve as atherosclerotic marker. Heart Vessels. 2008;23:390-6. doi:10.1007/s00380-008-1062-9.Jha HC, Prasad J, Mittal A. High immunoglobulin A seropositivity for combined Chlamydia pneumoniae, Helicobacter pylori infection, and high-sensitivity C-reactive protein in coronary artery disease patients in India can serve as atherosclerotic marker. Heart Vessels. 2008;23:390-6. doi:10.1007/s00380-008-1062-9.Roberts ET, Haan MN, Dowd JB, Aiello AE. Cytomegalovirus antibody levels, infammation, and mortality among elderly Latinos over 9 years of follow-up. Am J Epidemiol. 2010;172:363-71. doi:10.1093/aje/kwq177.Roberts ET, Haan MN, Dowd JB, Aiello AE. Cytomegalovirus antibody levels, infammation, and mortality among elderly Latinos over 9 years of follow-up. Am J Epidemiol. 2010;172:363-71. doi:10.1093/aje/kwq177.Spencer FA, Goldberg RJ, Becker RC, Gore JM. Seasonal distribution of acute myocardial infarction in the second National Registry of Myocardial Infarction. J Am Coll Cardiol. 1998;31:1226-33. doi:10.1016/s0735-1097(98)00098-9.Spencer FA, Goldberg RJ, Becker RC, Gore JM. Seasonal distribution of acute myocardial infarction in the second National Registry of Myocardial Infarction. J Am Coll Cardiol. 1998;31:1226-33. doi:10.1016/s0735-1097(98)00098-9.Barnes M, Heywood AE, Mahimbo A, et al. Acute myocardial infarction and influenza: a meta-analysis of case-control studies. Heart. 2015;101:1738-47. doi:10.1136/heartjnl-2015-307691.Barnes M, Heywood AE, Mahimbo A, et al. Acute myocardial infarction and influenza: a meta-analysis of case-control studies. Heart. 2015;101:1738-47. doi:10.1136/heartjnl-2015-307691.Vlachopoulos CV, Terentes-Printzios DG, Aznaouridis KA, et al. Association between pneumococcal vaccination and cardiovascular outcomes: a systematic review and metaanalysis of cohort studies. Eur J Prev Cardiol. 2015;22:1185-99. doi:10.1177/2047487314549512.Vlachopoulos CV, Terentes-Printzios DG, Aznaouridis KA, et al. Association between pneumococcal vaccination and cardiovascular outcomes: a systematic review and metaanalysis of cohort studies. Eur J Prev Cardiol. 2015;22:1185-99. doi:10.1177/2047487314549512.Diomedi M, Pietroiusti A, Silvestrini M, et al. CagA-positive Helicobacter pylori strains may influence the natural history of atherosclerotic stroke. Neurology. 2004;63:800-4. doi:10.1212/01.wnl.0000138025.82419.80.Diomedi M, Pietroiusti A, Silvestrini M, et al. CagA-positive Helicobacter pylori strains may influence the natural history of atherosclerotic stroke. Neurology. 2004;63:800-4. doi:10.1212/01.wnl.0000138025.82419.80.Lockhart PB, Bolger AF, Papapanou PN, et al. Periodontal disease and atherosclerotic vascular disease: does the evidence support an independent association?: a scientific statement from the American Heart Association. Circulation. 2012;125:2520-44. doi:10.1161/CIR.0b013e31825719f3.Lockhart PB, Bolger AF, Papapanou PN, et al. Periodontal disease and atherosclerotic vascular disease: does the evidence support an independent association?: a scientific statement from the American Heart Association. Circulation. 2012;125:2520-44. doi:10.1161/CIR.0b013e31825719f3.de Oliveira C, Watt R, Hamer M. Toothbrushing, inflammation, and risk of cardiovascular disease: results from Scottish Health Survey. BMJ. 2010;340:c2451. doi:10.1136/bmj.c2451.de Oliveira C, Watt R, Hamer M. Toothbrushing, inflammation, and risk of cardiovascular disease: results from Scottish Health Survey. BMJ. 2010;340:c2451. doi:10.1136/bmj.c2451.Hansen GM, Egeberg A, Holmstrup P, Hansen PR. Relation of periodontitis to risk of cardiovascular and all-cause mortality (from a Danish nationwide cohort study). Am J Cardiol. 2016;118:489-93. doi:10.1016/j.amjcard.2016.05.036.Hansen GM, Egeberg A, Holmstrup P, Hansen PR. Relation of periodontitis to risk of cardiovascular and all-cause mortality (from a Danish nationwide cohort study). Am J Cardiol. 2016;118:489-93. doi:10.1016/j.amjcard.2016.05.036.Beukers NGFM, van der Heijden GJMG, van Wijk AJ, Loos BG. Periodontitis is an independent risk indicator for atherosclerotic cardiovascular diseases among 60,174 participants in a large dental school in the Netherlands. J Epidemiol Community Health. 2017;71:37-42. doi:10.1136/jech-2015-206745.Beukers NGFM, van der Heijden GJMG, van Wijk AJ, Loos BG. Periodontitis is an independent risk indicator for atherosclerotic cardiovascular diseases among 60,174 participants in a large dental school in the Netherlands. J Epidemiol Community Health. 2017;71:37-42. doi:10.1136/jech-2015-206745.Virchow R. Cellular pathology. 1860.Virchow R. Cellular pathology. 1860.Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet (London, England). 2010;375:132-40. doi:10.1016/S0140-6736(09)61717-7.Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet (London, England). 2010;375:132-40. doi:10.1016/S0140-6736(09)61717-7.Wennberg P, Wensley F, Di Angelantonio E, et al. Haemostatic and inflammatory markers are independently associated with myocardial infarction in men and women. Thromb Res. 2012;129:68-73. doi:10.1016/j.thromres.2011.05.015.Wennberg P, Wensley F, Di Angelantonio E, et al. Haemostatic and inflammatory markers are independently associated with myocardial infarction in men and women. Thromb Res. 2012;129:68-73. doi:10.1016/j.thromres.2011.05.015.Sheedy FJ, Grebe A, Rayner KJ, et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile infammation. Nat Immunol. 2013;14:812-20. doi:10.1038/ni.2639.Sheedy FJ, Grebe A, Rayner KJ, et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile infammation. Nat Immunol. 2013;14:812-20. doi:10.1038/ni.2639.Després JP. Health consequences of visceral obesity. Ann Med. 2001;33:534-41. doi:10.3109/07853890108995963.Després JP. Health consequences of visceral obesity. Ann Med. 2001;33:534-41. doi:10.3109/07853890108995963.Altman R. Risk factors in coronary atherosclerosis atheroinflammation: the meeting point. Thromb J. 2003;1:1-11. doi:10.1186/1477-9560-1-4.Altman R. Risk factors in coronary atherosclerosis atheroinflammation: the meeting point. Thromb J. 2003;1:1-11. doi:10.1186/1477-9560-1-4.Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111-21. doi:10.1056/NEJMoa1701719.Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111-21. doi:10.1056/NEJMoa1701719.Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 defciency accelerates atherosclerosis development in mice. Science. 2017;355:842-7. doi:10.1126/science.aag1381.Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 defciency accelerates atherosclerosis development in mice. Science. 2017;355:842-7. doi:10.1126/science.aag1381.Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162:597-605. doi:10.1016/j.ahj.2011.06.012.Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162:597-605. doi:10.1016/j.ahj.2011.06.012.Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-31. doi:10.1056/NEJMoa1707914.Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-31. doi:10.1056/NEJMoa1707914.Dock W. Research in arteriosclerosis; the first fifty years. Ann Intern Med. 1958;49(3):699-705. doi:10.7326/0003-4819-49-3-699.Dock W. Research in arteriosclerosis; the first fifty years. Ann Intern Med. 1958;49(3):699-705. doi:10.7326/0003-4819-49-3-699.

The authors declare that there are no conflicts of interest present.